SHELBY
2021-03-15
Like and comment
Merck and Gilead announce partnership for long-acting HIV treatments
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
3
4
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":322478759,"tweetId":"322478759","gmtCreate":1615823443271,"gmtModify":1703493688144,"author":{"id":3574130506412388,"idStr":"3574130506412388","authorId":3574130506412388,"authorIdStr":"3574130506412388","name":"SHELBY","avatar":"https://static.tigerbbs.com/8ea388783a3408018293b98b9d8e4c4a","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":17,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like and comment </p></body></html>","htmlText":"<html><head></head><body><p>Like and comment </p></body></html>","text":"Like and comment","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/322478759","repostId":1163783799,"repostType":4,"repost":{"id":"1163783799","pubTimestamp":1615820076,"share":"https://www.laohu8.com/m/news/1163783799?lang=&edition=full","pubTime":"2021-03-15 22:54","market":"us","language":"en","title":"Merck and Gilead announce partnership for long-acting HIV treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=1163783799","media":"seekingalpha","summary":"Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize lon","content":"<p>Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize long-acting treatments targeting people living with HIV.</p><p>The combination will bring together two experimental therapies of companies: Gilead’s capsid inhibitor, lenacapavir, and Merck’s nucleoside reverse transcriptase translocation inhibitor, islatravir.</p><p>The initial focus of the collaboration will be an oral formulation, and its studies are set to begin in H2 2021.</p><p>Gilead and Merck will share global development and commercialization costs on a 60%/40% basis, respectively with Gilead leading the commercialization in the U.S. while Merck focuses on the EU and the rest of the world.</p><p>The companies will equally share the global product revenues until a certain threshold is met, and after net product sales for the oral combination reaches $2B a year, Gilead and Merck will apportion any revenues above the threshold on a ratio of 65%/ 35% respectively.</p><p>In January, ViiV Healthcare, a joint venture between GlaxoSmithKline(NYSE:GSK), Pfizer(NYSE:PFE)and Shionogi(OTCPK:SGIOY)received FDA approval for Cabenuva, cited as the first and only once-monthly, long-acting regimen for the treatment of HIV.</p><p><img src=\"https://static.tigerbbs.com/d47453449984c6102db13dec7df70ce3\" tg-width=\"1083\" tg-height=\"495\" referrerpolicy=\"no-referrer\"><img src=\"https://static.tigerbbs.com/035b5e3b38df0268f87dd33a8bde94ca\" tg-width=\"1083\" tg-height=\"495\" referrerpolicy=\"no-referrer\"></p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck and Gilead announce partnership for long-acting HIV treatments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck and Gilead announce partnership for long-acting HIV treatments\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-03-15 22:54 GMT+8 <a href=https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize long-acting treatments targeting people living with HIV.The combination will bring together two ...</p>\n\n<a href=\"https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GILD":"吉利德科学","MRK":"默沙东"},"source_url":"https://seekingalpha.com/news/3672687-merck-and-gilead-partnership-for-long-acting-hiv-treatments","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1163783799","content_text":"Merck(MRK+1.19%)has partnered with Gilead Sciences(GILD+1.07%)to co-develop and co-commercialize long-acting treatments targeting people living with HIV.The combination will bring together two experimental therapies of companies: Gilead’s capsid inhibitor, lenacapavir, and Merck’s nucleoside reverse transcriptase translocation inhibitor, islatravir.The initial focus of the collaboration will be an oral formulation, and its studies are set to begin in H2 2021.Gilead and Merck will share global development and commercialization costs on a 60%/40% basis, respectively with Gilead leading the commercialization in the U.S. while Merck focuses on the EU and the rest of the world.The companies will equally share the global product revenues until a certain threshold is met, and after net product sales for the oral combination reaches $2B a year, Gilead and Merck will apportion any revenues above the threshold on a ratio of 65%/ 35% respectively.In January, ViiV Healthcare, a joint venture between GlaxoSmithKline(NYSE:GSK), Pfizer(NYSE:PFE)and Shionogi(OTCPK:SGIOY)received FDA approval for Cabenuva, cited as the first and only once-monthly, long-acting regimen for the treatment of HIV.","news_type":1},"isVote":1,"tweetType":1,"viewCount":106,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":14,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/322478759"}
精彩评论